Psychedelic medicine survived its worst-case scenario -- the FDA's 2024 rejection of MDMA-assisted therapy and Lykos's subsequent collapse -- and the sector's regulatory leadership has passed to psilocybin: Compass Pathways' two clean Phase 3 wins plus an April 2026 White House executive order and FDA National Priority Vouchers make an early-2027 approval plausible, but nothing classic-psychedelic is approved yet and MDMA itself remains stalled behind a costly new pivotal trial.
📈 What changed: July 16, 2026: Eli Lilly agreed to acquire AtaiBeckley for up to $3.8B ($6.75/share cash plus up to $2.50/share in contingent value rights) -- the sector's largest big-pharma vali…
| Indicator | Score | Reading |
|---|---|---|
| Maturity higher is better · high confidence | 45/100 | A commercial ketamine node sits atop an otherwise pre-approval psychedelic pipeline; nothing classic (psilocybin/MDMA/5-MeO-DMT/LSD) has US approval yet. |
| Evidence Strength higher is better · high confidence | 75/100 | Regulator-issued and SEC-filed disclosures anchor the core claims; independent third-party replication is only partial since nothing is approved yet. |
| Commercial Proximity higher is better · high confidence | 50/100 | Compass Pathways has the sector's clearest near-term wedge, but it is a voucher-backed filing, not a proven approval, and MDMA's path is materially delayed. |
| Capital & Policy Support higher is better · high confidence | 48/100 | A genuine April-2026 White House/FDA tailwind is real but facilitative and administration-contingent, not a binding mandate or a large committed funding floor. |
| Crowding Risk lower is better · high confidence | 57/100 | A real post-EO re-rating hit a still-small, still-niche investable universe rather than a broadly owned trade. |
| Reflexivity Risk lower is better · high confidence | 85/100 | A pre-revenue, catalyst-driven cohort where single regulatory announcements -- in either direction -- have moved the whole sector sharply. |
Every indicator score is computed by the Northstar engine from analyst-set ordinal bands — never hand-written, never stored.
The public page is the summary (backed by 19 cited sources). Full briefing — company map, catalysts, native signals and sources — is inside the app.
Open in the appStart free →The Northstar Signal — what moved across all 350 themes and why, in your inbox. Free, no spam, one-click unsubscribe.